甲氨蝶呤联合口服泼尼松龙与三联疗法(甲氨蝶呤/柳氮磺吡啶/羟氯喹)联合关节腔内糖皮质激素治疗早期类风湿关节炎的比较:NORD-STAR试验常规治疗臂48周临床与影像学数据的预设非随机亚组分析
基于NORD-STAR试验常规治疗臂的预设非随机亚组分析,比较口服组(甲氨蝶呤联合口服泼尼松龙)与注射组(三联疗法联合强制关节腔内糖皮质激素注射)治疗早期类风湿关节炎48周的结局。注射组临床缓解率更高、感染更少、累积糖皮质激素剂量更低,但影像学进展略高;作者认为虽为非随机比较,结果提示常规治疗策略有优化潜力。
要点
- 48周时注射组临床疾病活动指数缓解率55%,口服组36%,风险差19%(95%CI 2-35)。
- 注射组感染发生率53%,口服组30%;注射组退出更少、不良事件更少。
- 口服组累积泼尼松龙剂量中位1905 mg,注射组165 mg;影像学进展均较低。
核心结论
- 在未经治疗的早期类风湿关节炎患者中,三联疗法联合强制关节腔内糖皮质激素注射相比甲氨蝶呤联合口服泼尼松龙,临床结局数值上更好、退出更少、不良事件更少、累积糖皮质激素剂量更低,但影像学结局略差。
- 这些发现虽为非随机比较,但提示常规治疗策略在早期类风湿关节炎中具有优化潜力。
研究设计与样本
- NORD-STAR试验常规治疗臂的预设非随机亚组分析,比较口服组(甲氨蝶呤联合口服泼尼松龙)与注射组(三联疗法联合强制关节腔内糖皮质激素注射)治疗早期类风湿关节炎48周的临床、患者报告、安全性和影像学结局。
- 口服组来自瑞典、挪威、荷兰和冰岛;注射组来自丹麦和芬兰。
- 共纳入口服组137例和注射组80例患者,分别有78%和89%完成研究。
- 主要终点采用逻辑回归分析,并采用多种方法处理缺失结局。
主要发现
- 48周时,调整后临床疾病活动指数缓解(≤2.8)率口服组为36%(95%CI 28-44),注射组为55%(95%CI 42-68);风险差(主要结局)为19%(95%CI 2-35)。
- 关键次要临床、患者报告和安全性结局在注射组相比口服组数值上更好,例如感染发生率口服组53% vs 注射组30%。
- 影像学进展(Δ总van der Heijde改良Sharp评分)较低:口服组调整均值0.26(95%CI 0.08-0.43);注射组调整均值0.80(95%CI 0.55-1.05)。
- 累积口服/关节腔内糖皮质激素剂量(中位数):口服组泼尼松龙1905 mg,注射组165 mg。
关键数值与推荐
- 口服组方案:甲氨蝶呤联合口服泼尼松龙20.0 mg/d,快速减量,第36周停药。
- 注射组方案:三联疗法(甲氨蝶呤、柳氮磺吡啶、羟氯喹)联合强制关节腔内糖皮质激素注射。
- 主要终点:48周时临床疾病活动指数缓解(≤2.8)率的风险差。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,这些非随机发现提示常规治疗策略在早期类风湿关节炎中具有优化潜力。
局限性
- 原文明确指出这些发现为非随机比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In the NOrdic Rheumatic Diseases Strategy Trials And Registries (NORD-STAR) trial, the active conventional arm had 2 nonrandomised regimens: arm 1A (oral group; Sweden, Norway, Netherlands, and Iceland) and arm 1B (injection group; Denmark and Finland). We report clinical, patient-reported, safety, and radiographic outcomes after 48 weeks. METHODS: Oral group received methotrexate plus oral prednisolone (20.0 mg/d, tapered rapidly, discontinued week 36); Injection group received triple therapy (methotrexate, sulphasalazine, hydroxychloroquine) and mandatory intra-articular glucocorticoid injections. The primary end point was analysed by logistic regression with several approaches for handling missing outcomes. RESULTS: In total, 137 and 80 patients were included in the oral group and injection group; 78% vs. 89% completed, respectively. At 48 weeks, adjusted clinical disease activity index remission ≤2.8 rates (95% CI) were 36% (28-44) and 55% (42-68), respectively; the risk difference (primary outcome) was 19% (2-35). Similarly, key secondary clinical, patient-reported and safety outcomes showed numerically better results in the injection group vs oral group, for example, infections occurred in 53% vs 30%, respectively. Radiographic progression (Δtotal van der Heijde-modified Sharp Score) was low: oral group: adjusted mean, 0.26 (95% CI, 0.08-0.43); injection group: adjustedd mean, 0.80 (95% CI, 0.55-1.05). Cumulative dose of oral/intra-articular glucocorticoids (median) was 1905 mg prednisolone for the oral group and 165 mg for the injection group. CONCLUSIONS: In treatment-naïve patients with early rheumatoid arthritis, triple therapy and mandatory glucocorticoid joint injections had numerically better clinical outcomes, fewer withdrawals, fewer adverse events, and lower cumulative dose of glucocorticoids, but slightly worse radiographic outcomes than treatment with methotrexate and oral prednisolone. These findings, although nonrandomised, suggest a potential for optimising treatment strategy with conventional therapies in early rheumatoid arthritis.
引用
- Hetland ML, Heiberg MS, Sokka-Isler T, et al. Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm. Ann Rheum Dis. 2025. PMID: 40188008. doi:10.1016/j.ard.2025.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。